EGFR and TP53 are important gene drivers in the early stages of lung adenocarcinoma development, but their frequency increases with advancing steps of histologic progression and were always present at the MIA stage; interestingly, the fractional abundancy of TP53 and EGFR mutations is higher in MIAs than in AISs [31]. This evidence concerns the gene EGFR and lung adenocarcinoma.